What is GHR-2 (GHRP-2)?
GHRP-2 is a synthetic growth hormone-releasing peptide that acts as a ghrelin/GHS receptor agonist. It stimulates pituitary GH release and is part of the older GHRP family that includes GHRP-6, GHRP-2, hexarelin, and ipamorelin.[8][6][9]
GHRP-2 is generally more potent for GH release than GHRP-6 and less selective than ipamorelin, with more cortisol and prolactin concern than the cleaner GHRP profile.[6][9]
GHRP-2 naming often overlaps with pralmorelin, KP-102, and growth hormone-releasing peptide-2. Those names point to the same ghrelin-receptor secretagogue family, but they do not make GHRP-2 interchangeable with GHRP-6, ipamorelin, or GHRH analogs.[8][6] For more context, read the GHRP-2 side-effect discussion.
What GHR-2 (GHRP-2) is investigated for
GHR-2 (GHRP-2) evidence is grouped by practical use case and injectable and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
GH release and IGF-1 response
Injectable
GH release and IGF-1 response
Injectable
Appetite and food-intake signaling
Injectable
Appetite and food-intake signaling
Injectable
Fat loss and lean mass
Injectable
Fat loss and lean mass
Injectable
Training recovery
Injectable
Training recovery
Injectable
Evidence snapshot
Overall confidence
GHRP-2 has credible human GH-secretagogue data and ghrelin-receptor pharmacology. Practical confidence is limited by missing approved therapeutic use and long-term outcome trials.[6][33][9]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Available human studies support GH and IGF-1 response, food-intake effects, diagnostic testing, and anti-doping detection. They do not establish long-term wellness outcomes.[6][33][9]
Animal / preclinical
Animal and cell studies support ghrelin/GHS receptor biology, food intake, inflammation, and tissue-model hypotheses. Those findings remain secondary to human endocrine limits.[12][28]
Mechanism support
Ghrelin/GHS receptor activation directly explains GH release, appetite effects, and off-target endocrine monitoring. Mechanistic confidence is stronger than outcome confidence.[6][9]
Forms & administration
GHRP-2 has short-acting injectable presentations and an investigational oral form with limited pediatric evidence. Oral preparation and weight-based amounts differ from injectable protocols; neither an adult oral product nor an interchangeable injection-to-oral dose is established.[6][33][9][41]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Typical Range
Injectable protocols use 100-300 mcg per dose. Intranasal protocols use 100 mcg per dose.[6][33][9][32][22]
Frequency
Injectable protocols use 2-3 doses daily. Intranasal protocols use 2 doses daily.[6][33][9][32][22]
Timing Considerations
Common timing is morning, before a workout, or before bed, usually away from food.[6][33][9][32][22]
Cycle Length
Injectable cycles run 8-12 weeks. Intranasal cycles run about 4 weeks.[6][33][9][32][22]
What to expect
First week
Injectable GH-pulse use may first show stronger hunger, sleep changes, water retention, or shifts in training-day recovery.[6][9]
Weeks 4-8
Appetite pattern, waist, training tolerance, recovery notes, IGF-1, and fasting glucose become clearer once timing and food windows are consistent.[6][33][9]
After stopping
Appetite, water retention, and IGF-1-related markers often drift toward baseline after short-acting GH secretagogue exposure ends.[8][6][9]
Safety profile
Injectable GHRP-2 safety centers on appetite change, water retention, glucose and IGF-1 effects, ACTH/cortisol/prolactin biology, injection quality, pregnancy avoidance, active malignancy caution, and sports prohibition.[6][33][9][35][38]
Who GHR-2 (GHRP-2) is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Diabetes medications
Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution.[6][33][9][35][38]
- Other GH-axis agents
GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable GHRP-2; this is a stack-level safety caution.[6][33][9][35][38]
Pairing notes
Not recommended with
This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[1][38][42]
Ipamorelin and GHRP-2 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[43][1][44][38]
GHRP-2 and GHRP-6 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[1][45][38]
GHRP-2 and Hexarelin both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[1][46][38]
Related peptides
Regulatory status
United States
GHRP-2 has no FDA-approved injectable U.S. use as of 2026-06-21. FDA warning-letter materials also state GHRP-2 was not eligible for 503A exemptions in that context because it was not on the bulks list or an approved-drug component.[35][38]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved As of 2026-06-21, GHRP-2 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval.[35][38] | Not Listed FDA warning-letter materials state that GHRP-2 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it.[38] |
Injectable
FDA drug approval
Not ApprovedAs of 2026-06-21, GHRP-2 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval.[35][38]
503A compounding
Not ListedFDA warning-letter materials state that GHRP-2 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it.[38]
International
EU/Europe, UK, Canada, and Australia should be checked by local medicine and compounding rules; any non-U.S. diagnostic or research context should not be generalized to therapeutic approval.
Sports & competition
WADA's 2026 Prohibited List treats GHRPs and growth hormone secretagogues as S2-prohibited; tested athletes should treat injectable GHRP-2 use as prohibited without a valid TUE.[40]
How it works
GHRP-2 is a ghrelin/GHS receptor agonist that triggers pituitary GH release rather than acting as replacement growth hormone. Human endocrine studies show GH and IGF-1 responses, and a separate appetite study shows that ghrelin-receptor signaling can affect food intake.[6][9]
For injectable use, that broader receptor biology matters because GHRP-2 is less selective than cleaner GH-secretagogue narratives suggest. The mechanism can overlap with appetite, glucose, fluid retention, cortisol, and prolactin interpretation; it does not prove long-term body-composition, recovery, sleep, or longevity benefit in people.[6][14]
Research gaps & open questions
What the current literature has not yet settled about GHR-2 (GHRP-2):
Long-term controlled studies need to show whether GHRP-2 improves fat loss, lean mass, recovery, or sleep, and how repeated use affects blood sugar, IGF-1, cortisol, and prolactin.[6][33][9]
Direct comparisons with other growth-hormone-releasing peptides should measure real benefits and side effects, not only the size of a temporary growth-hormone pulse.[6][9]
Athletes need clearer data on detection windows and product-contamination risk because GHRP-2 is prohibited in sport.[40]
Common questions
Is GHRP-2 FDA-approved?
Is GHRP-2 banned in tested sports?
Yes. WADA treats GHRPs and GH secretagogues such as GHRP-2 as S2-prohibited without a valid TUE.[40]
Myths & misconceptions
Myth
GHRP-2 is undetectable because it clears quickly.
Myth
GHRP-2 is safe because it stimulates natural GH.
History & discovery
GHRP-2, also known as pralmorelin, belongs to the synthetic secretagogue lineage that helped separate ghrelin/GHS-receptor pharmacology from direct growth hormone replacement.[8][6][9]
Phase I and older-adult studies used GHRP-2 to probe GH and IGF-1 responses, often alongside GHRH, before wellness-market protocols became common.[6][33][9]
Human obesity research showed GHRP-2 could stimulate food intake, helping connect the peptide with ghrelin-like appetite signaling as well as GH release.[9]
Urine detection work and WADA class rules made anti-doping status part of the modern history, while U.S. use remains outside FDA-approved injectable products.[40][16][35][38]
46 citations
Show citationsHide citations
- [1]Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.European journal of endocrinology, 1999 Jan. human clinical.
- [2]Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy.Metabolism: clinical and experimental, 1999 May. human clinical.
- [3]The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine.Domestic animal endocrinology, 2000 Apr. animal.
- [4]Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine.Domestic animal endocrinology, 2001 Jan. animal.
- [5]Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.Endocrine, 2001 Feb. review.
- [6]Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.Endocrine, 2001 Feb. human clinical.
- [7]Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks.European journal of pharmacology, 2002 Oct 18. animal.
- [8]Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.Drugs in R&D, 2004. review.
- [9]Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.Obesity (Silver Spring, Md.), 2006 Jun. human clinical.
- [10]Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism.Endocrine journal, 2008 Aug. review.
- [11]The effect of growth hormone releasing peptide-2 on upper gastrointestinal contractile activity and food intake in conscious dogs.Journal of gastroenterology, 2009. animal.
- [12]Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary.Regulatory peptides, 2009 Nov 27. animal.
- [13]Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report.Neurologia medico-chirurgica, 2009 Aug. review.
- [14]Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study.Peptides, 2010 Apr. review.
- [15]Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.Endocrine journal, 2010. review.
- [16]Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry.Rapid communications in mass spectrometry : RCM, 2010 Jul 30. review.
- [17]Growth hormone releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats.The Tohoku journal of experimental medicine, 2010 Sep. animal.
- [18]Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement.Drug testing and analysis, 2010 Mar. review.
- [19]Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects.Drug testing and analysis, 2010 Nov-Dec. review.
- [20]Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice.Clinics (Sao Paulo, Brazil), 2012. animal.
- [21]Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity.AAPS PharmSciTech, 2015 Oct. review.
- [22]One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient.Journal of cachexia, sarcopenia and muscle, 2015 Sep. review.
- [23]Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure.Endocrine journal, 2016 Jun 30. human clinical.
- [24]Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.International journal of molecular sciences, 2016 Aug 19. in vitro.
- [25]Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas.Endocrine journal, 2018 Oct 29. review.
- [26]Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.Journal of the Endocrine Society, 2022 Aug 1. review.
- [27]Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2023 Aug. review.
- [28]Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model.Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025 Jul. animal.
- [29]Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.The Journal of clinical endocrinology and metabolism, 1995 Oct. human clinical.
- [30]Effects of growth hormone-releasing peptide-2 (GHRP-2) on membrane Ca2+ permeability in cultured ovine somatotrophs.Journal of neuroendocrinology, 1995 Mar. in vitro.
- [31]Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves.Endocrine journal, 1996 Jun. animal.
- [32]Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.The Journal of endocrinology, 1997 Oct. human clinical.
- [33]Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.The Journal of clinical endocrinology and metabolism, 1998 Apr. human clinical.
- [34]Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours.Journal of neuroendocrinology, 1998 Jun. in vitro.
- [35]Drugs@FDA/openFDA query for GHRP-2U.S. Food and Drug Administration / openFDA. database query.
- [36]Drugs@FDA/openFDA query for PralmorelinU.S. Food and Drug Administration / openFDA. database query.
- [37]Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic ActU.S. Food and Drug Administration, 2026-05-14. regulatory.
- [38]United Pharmacy MARCS-CMS 553916 - February 11, 2019U.S. Food and Drug Administration, 2019-02-11. regulatory.
- [39]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [40]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency, 2026. regulatory.
- [41]Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.Journal of pediatric endocrinology & metabolism : JPEM, 2003 Sep. human clinical.
- [42]NORDITROPIN somatropin injection prescribing informationU.S. Food and Drug Administration. official guidance.
- [43]Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research, 1999 Sep. human clinical.
- [44]October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document 4 - IpamorelinU.S. Food and Drug Administration, 2024-10-29. regulatory.
- [45]Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal agingEuropean Journal of Endocrinology, 1994-11. human clinical.
- [46]Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.European Journal of Endocrinology, 1996 Oct. human clinical.


